Market Size of Global Immunosuppressant Drugs Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Immunosuppressant Drugs Market Analysis
The immunosuppressant drugs market is expected to register a CAGR of 4.6% during the forecast period.
The COVID-19 pandemic had a significant effect on the market. For instance, according to an article published by PubMed Central in April 2022, there was a 16% global reduction in transplant activity during the initial pandemic, resulting in a substantial impact on the waitlisted patient. Reduced organ transplants meant a reduction in the usage of immunosuppressant drugs as well. However, as the pandemic has subsided, the studied market is expected to grow.
Factors such as the growing prevalence of autoimmune diseases, the rise in organ transplants, and technological advancements in tissue engineering and organ transplantations are expected to enhance the market growth.
The increasing prevalence of autoimmune diseases is a major factor that is expected to enhance the market growth. For instance, according to an article updated by the NCBI in April 2022, around 2.5 million people worldwide have multiple sclerosis, and the article also stated that females are three times more prone to develop the illness than males.
Furthermore, according to an article published by MDPI in July 2022, Rheumatoid arthritis (RA) is considered a common autoimmune illness that manifests majorly as chronic, symmetric, and progressive polyarthritis with a global frequency of 0.3-1.0%. This will lead to increased adoption of immunosuppressant drugs for RA, driving market growth.
Product approval is another major factor for market growth. For instance, in February 2022, China's National Medical Products Administration (NMPA) approved GlaxoSmithKline's Benlysta for the treatment of adult patients with active lupus nephritis (LN) in China.
While growth is expected, stringent regulatory processes are expected to hinder the market growth.
Immunosuppressant Drugs Industry Segmentation
Immunosuppressant drugs inhibit or prevent the activity of the immune system, and they are used to prevent the rejection of a transplanted organ and to treat autoimmune diseases.
The Immunosuppressant Drugs Market is segmented By Drug Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, and Other Drug Classes), Application (Autoimmune diseases (Systemic Autoimmune Disease, and Localized Autoimmune Disease), Organ transplant, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Drug Class | |
| Calcineurin Inhibitors | |
| Antiproliferative Agents | |
| mTOR Inhibitor | |
| Steroids | |
| Other Drug Classes |
| By Application | ||||
| ||||
| Organ transplant | ||||
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Immunosuppressant Drugs Market Size Summary
The immunosuppressant drugs market is poised for growth, driven by factors such as the increasing prevalence of autoimmune diseases, advancements in organ transplantation technologies, and the approval of new products. The market experienced a temporary setback during the COVID-19 pandemic due to reduced transplant activities, which subsequently decreased the demand for immunosuppressants. However, as the pandemic's impact wanes, the market is expected to recover and expand. The rising incidence of autoimmune conditions, such as rheumatoid arthritis and systemic lupus erythematosus, is anticipated to boost the adoption of immunosuppressant therapies. Additionally, technological progress in tissue engineering and organ transplantation is likely to further propel market growth.
North America is expected to maintain a significant share of the immunosuppressant drugs market, attributed to the high prevalence of autoimmune diseases and a growing number of organ transplants in the region. The market is characterized by fragmentation, with several major players like Astellas Pharma, Sanofi, and Bristol-Myers Squibb holding substantial market shares. The increasing research investment in autoimmune diseases and the introduction of new therapies are expected to enhance the market landscape. Despite the promising growth prospects, the market faces challenges from stringent regulatory processes that could impede its expansion.
Global Immunosuppressant Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Growing Prevalence of Autoimmune Diseases and Rise in the Number of Organ Transplants
-
1.2.2 Technological Advancements in Tissue Engineering and Organ Transplantations
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulatory Processes
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Drug Class
-
2.1.1 Calcineurin Inhibitors
-
2.1.2 Antiproliferative Agents
-
2.1.3 mTOR Inhibitor
-
2.1.4 Steroids
-
2.1.5 Other Drug Classes
-
-
2.2 By Application
-
2.2.1 Autoimmune diseases
-
2.2.1.1 Systemic Autoimmune Disease
-
2.2.1.2 Localized Autoimmune Disease
-
-
2.2.2 Organ transplant
-
2.2.3 Other Applications
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Immunosuppressant Drugs Market Size FAQs
What is the current Global Immunosuppressant Drugs Market size?
The Global Immunosuppressant Drugs Market is projected to register a CAGR of 4.60% during the forecast period (2024-2029)
Who are the key players in Global Immunosuppressant Drugs Market?
Astellas Pharma, Inc, Sanofi (Genzyme), Bristol-Myers Squibb Company, Novartis AG and F. Hoffmann-La Roche Ltd are the major companies operating in the Global Immunosuppressant Drugs Market.
